Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Feb. 16, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) investors that a class action lawsuit filed on behalf of investors that purchased Talis shares pursuant to the Company’s February 2021 initial public offering.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 1-844-PORTLAW (844-767-8529) or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: the comparator assay in the primary study lacked sufficient sensitivity to support Talis’ Emergency Use Authorization (“EUA”) application for Talis One COVID-19 test; as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; as a result, the Company’s commercialization timeline would be significantly delayed; and as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
